SARS-CoV-2抗体-话题@MedSci

#SARS-CoV-2抗体#

8篇内容 | 796人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1685500, encodeId=8816168550078, content=<a href='/topic/show?id=7c3b1590400' target=_blank style='color:#2F92EE;'>#SARS-CoV-2抗体#</a>, objectTitle=Lancet Rheumatology: 抑制IL-1和IL-6影响COVID-19患者抗SARS-CoV-2抗体的中和活性, objectType=article, longId=219599, objectId=a5c321959961, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a5c321959961, replyNumber=0, likeNumber=0, createdTime=2022-09-08, rootId=0, userName=晓辰, userId=499e28204717, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a5c321959961, moduleTitle=Lancet Rheumatology: 抑制IL-1和IL-6影响COVID-19患者抗SARS-CoV-2抗体的中和活性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a5c321959961)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1685498, encodeId=e1d5168549854, content=<a href='/topic/show?id=7c3b1590400' target=_blank style='color:#2F92EE;'>#SARS-CoV-2抗体#</a>, objectTitle=Lancet：武汉地区一般人群抗SARS-CoV-2抗体阳性率不足7%，疫苗接种至关重要, objectType=article, longId=208735, objectId=a40c208e3526, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a40c208e3526, replyNumber=0, likeNumber=37, createdTime=2021-04-22, rootId=0, userName=晓辰, userId=499e28204717, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a40c208e3526, moduleTitle=Lancet：武汉地区一般人群抗SARS-CoV-2抗体阳性率不足7%，疫苗接种至关重要, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a40c208e3526)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1685499, encodeId=308c1685499d9, content=<a href='/topic/show?id=7c3b1590400' target=_blank style='color:#2F92EE;'>#SARS-CoV-2抗体#</a>, objectTitle=GUT：英夫利昔单抗治疗IBD患者的抗SARS-CoV-2抗体反应减弱, objectType=article, longId=209005, objectId=ad36209005e9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ad36209005e9, replyNumber=0, likeNumber=34, createdTime=2021-06-21, rootId=0, userName=晓辰, userId=499e28204717, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ad36209005e9, moduleTitle=GUT：英夫利昔单抗治疗IBD患者的抗SARS-CoV-2抗体反应减弱, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ad36209005e9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1685497, encodeId=3ef3168549e7e, content=<a href='/topic/show?id=7c3b1590400' target=_blank style='color:#2F92EE;'>#SARS-CoV-2抗体#</a>, objectTitle=Lancet：**波新冠肺炎疫情中，美国SARS-CoV-2抗体阳性率研究, objectType=article, longId=202497, objectId=165220249eb4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=165220249eb4, replyNumber=0, likeNumber=33, createdTime=2021-03-13, rootId=0, userName=晓辰, userId=499e28204717, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=165220249eb4, moduleTitle=Lancet：**波新冠肺炎疫情中，美国SARS-CoV-2抗体阳性率研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=165220249eb4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1685496, encodeId=ddc216854962f, content=<a href='/topic/show?id=7c3b1590400' target=_blank style='color:#2F92EE;'>#SARS-CoV-2抗体#</a>, objectTitle=芝加哥大学医学院：开始测试抗SARS-CoV-2抗体的疗效, objectType=article, longId=200278, objectId=e2552002e822, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e2552002e822, replyNumber=0, likeNumber=31, createdTime=2021-01-16, rootId=0, userName=晓辰, userId=499e28204717, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e2552002e822, moduleTitle=芝加哥大学医学院：开始测试抗SARS-CoV-2抗体的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e2552002e822)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1685495, encodeId=85561685495f8, content=<a href='/topic/show?id=7c3b1590400' target=_blank style='color:#2F92EE;'>#SARS-CoV-2抗体#</a>, objectTitle=Clinica Chimica Acta：两种半定量免疫检测方法在急诊科、住院和康复患者中的SARS-CoV-2抗体特性如何？, objectType=article, longId=197788, objectId=633119e78839, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=633119e78839, replyNumber=0, likeNumber=31, createdTime=2020-08-21, rootId=0, userName=晓辰, userId=499e28204717, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=633119e78839, moduleTitle=Clinica Chimica Acta：两种半定量免疫检测方法在急诊科、住院和康复患者中的SARS-CoV-2抗体特性如何？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=633119e78839)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1685493, encodeId=deb4168549305, content=<a href='/topic/show?id=7c3b1590400' target=_blank style='color:#2F92EE;'>#SARS-CoV-2抗体#</a>, objectTitle=日本研发出新型SARS-CoV-2抗体, objectType=article, longId=194053, objectId=eac0194053be, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=eac0194053be, replyNumber=0, likeNumber=28, createdTime=2021-01-15, rootId=0, userName=晓辰, userId=499e28204717, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=eac0194053be, moduleTitle=日本研发出新型SARS-CoV-2抗体, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=eac0194053be)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1685494, encodeId=388a168549456, content=<a href='/topic/show?id=7c3b1590400' target=_blank style='color:#2F92EE;'>#SARS-CoV-2抗体#</a>, objectTitle=重磅！Moderna的mRNA疫苗可激发健康志愿者产生SARS-CoV-2抗体, objectType=article, longId=194442, objectId=298e1944429a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=298e1944429a, replyNumber=0, likeNumber=34, createdTime=2021-01-23, rootId=0, userName=晓辰, userId=499e28204717, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=298e1944429a, moduleTitle=重磅！Moderna的mRNA疫苗可激发健康志愿者产生SARS-CoV-2抗体, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=298e1944429a)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

SARS-CoV-2抗体

2020-05-29

晓辰 (审核中...)

前往app查看评论内容

#SARS-CoV-2抗体#

Lancet Rheumatology: 抑制IL-1和IL-6影响COVID-19患者抗SARS-CoV-2抗体的中和活性

2022-09-08

晓辰 (审核中...)

前往app查看评论内容

#SARS-CoV-2抗体#

Lancet：武汉地区一般人群抗SARS-CoV-2抗体阳性率不足7%，疫苗接种至关重要

2021-04-22

晓辰 (审核中...)

前往app查看评论内容

#SARS-CoV-2抗体#

GUT：英夫利昔单抗治疗IBD患者的抗SARS-CoV-2抗体反应减弱

2021-06-21

晓辰 (审核中...)

前往app查看评论内容

#SARS-CoV-2抗体#

Lancet：**波新冠肺炎疫情中，美国SARS-CoV-2抗体阳性率研究

2021-03-13

晓辰 (审核中...)

前往app查看评论内容

#SARS-CoV-2抗体#

芝加哥大学医学院：开始测试抗SARS-CoV-2抗体的疗效

2021-01-16

晓辰 (审核中...)

前往app查看评论内容

#SARS-CoV-2抗体#

Clinica Chimica Acta：两种半定量免疫检测方法在急诊科、住院和康复患者中的SARS-CoV-2抗体特性如何？

2020-08-21

晓辰 (审核中...)

前往app查看评论内容

#SARS-CoV-2抗体#

日本研发出新型SARS-CoV-2抗体

2021-01-15

晓辰 (审核中...)

前往app查看评论内容

#SARS-CoV-2抗体#

重磅！Moderna的mRNA疫苗可激发健康志愿者产生SARS-CoV-2抗体

2021-01-23

科室
- - 订阅+
  - 更多科室
工具
服务